Overview

* PacBio Q3 2025 revenue declines to $38.4 mln from $40 mln in Q3 2024

* Adjusted EPS beats analyst expectations

* Record consumable revenue achieved, contributing to improved gross margins

Outlook

* Company expects SPRQ-Nx chemistry to reduce sequencing costs by up to 40%

* PacBio aims to make long-read sequencing more economically competitive

* Company expands PureTarget portfolio to support high throughput sequencing

Result Drivers

* CONSUMABLE REVENUE - Record consumable revenue achieved, contributing to improved gross margins

* CHINA APPROVAL - Sequel II CNDx system received Class III Medical Device Registration approval in China

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat -$0.12 -$0.16

Adjusted (4

EPS Analysts

)

Q3 EPS -$0.13

Q3 Beat -$36.85 -$45.28

Adjusted mln mln (5

Net Analysts

Income )

Q3 $16.16

Adjusted mln

Gross

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 7 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

* Wall Street's median 12-month price target for Pacific Biosciences of California Inc ( PACB ) is $1.65, about 21.2% below its November 4 closing price of $2.00

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)